- Went public, Jul 2018
- Raised $6.6M funding round, Dec 2023
- Raised $14.3M funding round, Dec 2019
About
Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics. The company currently conducts clinical trials utilizing its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal tract.
Entera Bio's technology addresses the two major problems of oral drug delivery of large-molecule active pharmaceutical ingredients. Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. Entera's proprietary technologies act synergistically to transport and protect large molecules.
The company is developing first-in-class, daily tablet protein and peptide replacement therapies, designed for patients to live healthier and injection-free, as they manage their chronic diseases.
Entera Bio is subsidiary of DNA Biomedical Solutions.
Funding history · 6 rounds · $58.9M total
Q&A
- What was Entera Bio's most recent funding round?
- In December 2023, Entera Bio closed a private placement, raising $6.6 million. This funding is intended for general working capital and extends the company's cash runway into 2025.
- What is Entera Bio's primary focus in drug development?
- Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics. They are developing first-in-class, daily tablet protein and peptide replacement therapies for chronic diseases, aiming to provide injection-free solutions.
- What is the status of Entera Bio's lead product candidate, EB613?
- EB613 is Entera Bio's most advanced product candidate, an oral treatment for post-menopausal women with osteoporosis. In July 2025, the FDA agreed to support the NDA marketing application for EB613 with a single Phase 3 study, using Bone Mineral Density (BMD) as the primary endpoint.
- What is Entera Bio's collaboration with OPKO Health focused on?
- Entera Bio has multiple collaborations with OPKO Health, Inc. These include developing an oral dual agonist GLP-1/glucagon peptide for treating obesity and metabolic disorders, and an oral GLP-2 analog for short bowel syndrome. They are leveraging Entera's N-Tab™ technology for these oral tablet formulations.
- What is the current employee count at Entera Bio?
- Entera Bio has an employee count in the 11-50 range.
- What was Entera Bio's market capitalization as of its IPO?
- In July 2018, Entera Bio listed on NASDAQ with a company valuation of $91 million, raising $11 million.
- What is Entera Bio's strategy for advancing its osteoporosis drug, EB613?
- Entera Bio is preparing for a pivotal Phase 3 study of EB613. The company has submitted a full qualification plan to the FDA for the use of bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs, which could accelerate the approval process.
- What is the status of Entera Bio's EB612 program?
- The EB612 program is developing the first oral PTH(1-34) tablet peptide replacement therapy for patients suffering from hypoparathyroidism. In June 2024, Entera Bio reported positive Phase 1 clinical data for EB612, reaffirming the capability of their N-Tab™ platform.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | enterabio.com |
|---|---|
| linkedin.com/company/8212212 | |
| facebook.com/Entera-Bio-%D7%9E%D7%97%D7%A7%D7%A8-%D7%9C%D7%A |
Identifiers & details
| Founded | 2009-9 |
|---|---|
| Employees (exact) | 22 |
| Market cap | $89.0M |
| Status reason | Public on NASDAQ on Jul, 2018; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2018-07 | $11.0M |